Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) have earned an average recommendation of “Moderate Buy” from the six ratings firms that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $9.20.

PYXS has been the topic of a number of analyst reports. HC Wainwright reiterated a “buy” rating and set a $5.00 price objective (down from $7.00) on shares of Pyxis Oncology in a research note on Friday, December 20th. William Blair lowered shares of Pyxis Oncology from an “outperform” rating to a “market perform” rating in a research report on Thursday, November 21st. Stephens assumed coverage on shares of Pyxis Oncology in a research note on Friday, November 8th. They issued an “overweight” rating and a $13.00 price objective on the stock. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $8.00 target price (down previously from $10.00) on shares of Pyxis Oncology in a research note on Friday, December 20th.

Pyxis Oncology Stock Performance

PYXS opened at $1.14 on Wednesday. The firm has a market cap of $67.79 million, a P/E ratio of -1.11 and a beta of 1.06. The business’s fifty day moving average is $1.46 and its 200-day moving average is $2.58. Pyxis Oncology has a 52-week low of $1.07 and a 52-week high of $6.79.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Intech Investment Management LLC acquired a new position in Pyxis Oncology in the 3rd quarter valued at approximately $55,000. SG Americas Securities LLC bought a new stake in shares of Pyxis Oncology in the third quarter worth $58,000. ProShare Advisors LLC acquired a new stake in Pyxis Oncology in the fourth quarter valued at $26,000. MetLife Investment Management LLC raised its position in Pyxis Oncology by 41.1% during the 3rd quarter. MetLife Investment Management LLC now owns 18,818 shares of the company’s stock worth $69,000 after purchasing an additional 5,484 shares during the last quarter. Finally, Ameriprise Financial Inc. acquired a new position in Pyxis Oncology during the 4th quarter worth about $35,000. Institutional investors own 39.09% of the company’s stock.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.